ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Glabridin-Gold(I) Complex as a Novel Immunomodulatory Agent Targeting TrxR and MAPK Pathways for Synergistic Enhancement of Antitumor Immunity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Au(III) Complexes as Pyroptosis Inducers by Targeting Mitochondrial DNA for Tumor Immunity.Angewandte Chemie (International ed. in English) · 2026Article
- Article
- Golden immunity: gold complexes as emerging triggers of immunogenic cell death.Chemical science · 2026Review
- Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.iScience · 2026Article
- Synergistic Activation of Immunogenic Cell Death and the cGAS-STING Pathway by Engineered Zinc/Manganese-Based Metal-Organic Framework Nanoplatforms for Colon Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ROS-Mediated Apoptosis Induction by a Cationic Pyridoxal Benzoylhydrazone Copper Complex in Oral Cancer Cells.ACS omega · 2026Article
- NewInternational journal of molecular sciences · 2026Article
- Thiosugar-functionalized gold(I)-NHC complexes as selective anticancer agents for potential targeted therapy.Frontiers in chemistry · 2026Article
- Glabridin-Gold(I) Complex as a Novel Immunomodulatory Agent Targeting TrxR and MAPK Pathways for Synergistic Enhancement of Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-based drugs have been utilized as immunomodulatory agents in combination with cancer immunotherapies to induce tumor immunogenicity. However, the immunosuppressive tumor microenvironment significantly hinders the efficacy of these immunomodulatory agents from promoting antitumor immune responses. Herein, a novel metal-based immunomodulatory agent, 6d, is developed by integrating N-heterocyclic carbene gold(I) [NHC-Au(I)] with the natural product glabridin (GLA). Complex 6d aims to promote tumor immunogenicity while suppressing immunosuppression, by targeting thioredoxin reductase (TrxR) and the mitogen-activated protein kinase (MAPK) pathways. Notably, 6d enhances dendritic cell (DC) maturation while reducing myeloid-derived suppressor cells (MDSCs), M2-type macrophages, and regulatory T cells (Tregs) in liver cancer. Moreover, 6d exhibits a synergistic effect of gold center and GLA, suppressing programmed cell death 1 ligand 1 (PD-L1) expression in tumor cells while promoting granzyme B (GzmB) production in T cells. These findings suggest that dual inhibition of TrxR and MAPK may provide a synergistic strategy to stimulate antitumor immunity while mitigating the immunosuppressive tumor microenvironment. Overall, this study warrants further researches to determine therapeutic efficacy of 6d as an immunomodulatory agent in combination with cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.